Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: Results of a Markov model for UK costs using data registries-Reference-Cited by-同舟云学术

Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: Results of a Markov model for UK costs using data registries

Published:2008-08 Issue:8 Volume:30 Page:1508-1523
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

ARA R,PANDOR A,TUMUR I,PAISLEY S,DUENAS A,WILLIAMS R,WILKINSON A,DURRINGTON P,CHILCOTT J

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies;PLOS ONE;2022-06-16

2. Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies;2022-02-15

3. Have We Learnt all from IMPROVE-IT? Part II. Subanalyses of the Effects of Ezetimibe Added to Statin Therapy on Selected Clinical and Laboratory Outcomes, Cost-Effectiveness, Guidelines, and Clinical Implications;Current Vascular Pharmacology;2021-09

4. The cost-effectiveness and cost-utility of statin drug for the treatment of patients with cardiovascular disease, a systematic review;International Journal of Preventive Medicine;2021

Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis

;Drug Design, Development and Therapy;2020-01